| Literature DB >> 34127511 |
Michael Dohopolski1, Sujana Gottumukkala1, Daniel Gomez2, Puneeth Iyengar1.
Abstract
The management of non-small-cell lung cancer (NSCLC) varies according to stage. Surgical resection is reserved for operable patients with early-stage NSCLC, while high-dose target radiation-stereotactic body radiation therapy (SBRT)-is reserved for patients whose comorbidities prohibit them from a major surgical procedure. The treatment of locally advanced NSCLC (LA-NSCLC) is stratified according to resectability. Those with resectable disease may require additional treatments such as chemotherapy and radiation, while patients with unresectable disease will require definitive chemoradiation therapy with adjuvant durvalumab. Patients with limited metastatic disease benefit from the combination of SBRT and systemic therapy.Entities:
Mesh:
Year: 2021 PMID: 34127511 PMCID: PMC8485739 DOI: 10.1101/cshperspect.a037713
Source DB: PubMed Journal: Cold Spring Harb Perspect Med ISSN: 2157-1422 Impact factor: 6.915